Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes

被引：0
|
作者：
Nathwani, Ameet
Lebeaut, Alexandre
Byiers, Stuart
Gimpelewicz, Claudio
Chang, Ih
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [21] Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
    Bosi, E.
    Dotta, F.
    Jia, Y.
    Goodman, M.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 506 - 515
  • [22] Comparative Efficacy of Metformin and Sulfonylurea in Monotherapy or Combination for Type 2 Diabetes
    Eltaib, Lina
    Alenzi, Shamayl M.
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2020, 12 (04) : 223 - 233
  • [23] Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
    Rombopoulos, Grigorios
    Hatzikou, Magdalini
    Athanasiadis, Athanasios
    Elisaf, Moyses
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [24] Vildagliptin Efficacy in Combination with MetfoRmIn for EarlY Treatment of Type 2 Diabetes Mellitus (VERIFY)
    Sheu, Wayne Huey-Herng
    Prato, Stefano D.
    Foley, James
    Kothny, Wolfgang
    Kozlovski, Plamen
    Paldanius, Paeivi
    Stumvoll, Michael
    Matthews, David R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 254 - 255
  • [25] Vildagliptin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy: efficacy and tolerance at 52 weeks
    Halimi, S.
    Dejager, S.
    Arnou, R.
    Delamare, G.
    Ferrannini, E.
    DIABETES & METABOLISM, 2009, 35 : A8 - A8
  • [26] Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablete
    Halimi, Serge
    Schweizer, Anja
    Minic, Biljana
    Foley, James
    Dejager, Sylvie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (03) : 481 - 492
  • [27] Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes
    Wu, Tongzhi
    Trahair, Laurence G.
    Little, Tanya J.
    Bound, Michelle J.
    Zhang, Xiang
    Wu, Hang
    Sun, Zilin
    Horowitz, Michael
    Rayner, Christopher K.
    Jones, Karen L.
    DIABETES CARE, 2017, 40 (05) : 702 - 705
  • [28] Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
    Rosenstock, J.
    Baron, M. A.
    Camisasca, R. -P.
    Cressier, F.
    Couturier, A.
    Dejager, S.
    DIABETES OBESITY & METABOLISM, 2007, 9 (02): : 175 - 185
  • [29] Factors associated with clinical inertia in type 2 diabetes mellitus patients treated with metformin monotherapy
    Kartoun, Uri
    Iglay, Kristy
    Shankar, R. Ravi
    Beam, Andrew
    Radican, Larry
    Chatterjee, Arnaub
    Rai, Jennifer K.
    Shaw, Stanley
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2063 - 2070
  • [30] Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
    Lukashevich, V.
    Prato, S. D.
    Araga, M.
    Kothny, W.
    DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 403 - 409
12345